Eberconazole is an imidazole antifungal that can be applied topically to treat dermatophytosis, candidiasis, and pityriasis. The impurity profile includes structurally similar analogs, residual solvents, and the degradation products that arise under stress conditions like hydrolysis, oxidation, and photolysis. The degradation pathways generally include oxidative cleavage of aromatic substituents, hydrolytic cleavage of amide bonds, and rearrangements of heteroaromatic moieties. These impurities can compromise the potency, stability, and safety of the drug. All identified impurities are structurally characterized and qualified by ICH guidelines for toxicology assessment and analytical validation.
We have Pharamacopeial and Non-pharmacopeial Eberconazole impurities offered in compliance with European Pharmacopoeia (EP) specification. These standards can be used in analytical method development, impurity profiling, and long-term stability studies. EP traceable materials are provided with verified analytical data, such as purity, structural confirmation, and spectral characterization.
Structural analogues related to Eberconazole and synthetic carbamate derivatives are included for identification of impurities, toxicological qualification, and regulatory submission. These related substances are used in studies of forced degradation, genotoxicity, and impurity thresholds. They are essential for understanding the impurity profile and ensuring compliance with regulatory limits.
We provide the Eberconazole impurity reference standards with validated analytical data, including purity, NMR, MS, and full Certificates of Analysis. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.
Register to add the product to RFQ list
Already have an account? Log in here
Don’t have an account? Register here
